The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid Profiling
Open accessAbstract
There has been limited analysis of the effects of hepatocellular carcinoma (HCC) on liver metabolism and circulating endogenous metabolites. Here, we report the findings of a plasma metabolomic investigation of HCC patients by ultraperformance liquid chromatography-electrospray ionization-quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOFMS), random forests machine learning algorithm, and multivariate data analysis. Control subjects included healthy individuals as well as patients with liver cirrhosis or acute myeloid leukemia. We found that HCC was associated with increased plasma levels of glycodeoxycholate, deoxycholate 3-sulfate, and bilirubin. Accurate mass measurement also indicated upregulation of biliverdin and the fetal bile acids 7α-hydroxy-3-oxochol-4-en-24-oic acid and 3-oxochol-4,6-dien-24-oic acid in HCC patients. A quantitative lipid profiling of patient plasma was also conducted by ultraperformance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry (UPLC-ESI-TQMS). By this method, we found that HCC was also associated with reduced levels of lysophosphocholines and in 4 of 20 patients with increased levels of lysophosphatidic acid [LPA(16:0)], where it correlated with plasma α-fetoprotein levels. Interestingly, when fatty acids were quantitatively profiled by gas chromatography-mass spectrometry (GC-MS), we found that lignoceric acid (24:0) and nervonic acid (24:1) were virtually absent from HCC plasma. Overall, this investigation illustrates the power of the new discovery technologies represented in the UPLC-ESI-QTOFMS platform combined with the targeted, quantitative platforms of UPLC-ESI-TQMS and GC-MS for conducting metabolomic investigations that can engender new insights into cancer pathobiology. Cancer Res; 71(21); 6590–600. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Mass spectrometry‐based metabolomics
Dettmer, K., Aronov, P. A., & Hammock, B. D. (2007) · Mass Spectrometry Reviews · doi:10.1002/mas.20108 · Cited by 2,241
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†
Wurmbach, E., Chen, Y., Khitrov, G., Zhang, W., Roayaie, S., Schwartz, M., Fiel, I., Thung, S., Mazzaferro, V., Bruix, J., et al. (2007) · Hepatology · doi:10.1002/hep.21622 · Cited by 722
Okabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y., & Nakamura, Y. (2001) · PubMed · Cited by 546
Lee, J.-S., Chu, I.-S., Mikaelyan, A., Calvisi, D. F., Heo, J., Reddy, J. K., & Thorgeirsson, S. S. (2004) · Nature Genetics · doi:10.1038/ng1481 · Cited by 475
The role of metabolites and metabolomics in clinically applicable biomarkers of disease
Mamas, M., Dunn, W. B., Neyses, L., & Goodacre, R. (2011) · Archives of Toxicology · doi:10.1007/s00204-010-0609-6 · Cited by 376
General, Applied and Systems Toxicology
(2009) · Wiley eBooks · doi:10.1002/9780470744307 · Cited by 342
Cited by
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Wong, V. W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 506
Lipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
A Review of Applications of Metabolomics in Cancer
Beger, R. (2013) · Metabolites · doi:10.3390/metabo3030552 · Cited by 288
Metabolomics for Biomarker Discovery: Moving to the Clinic
Zhang, A., Sun, H., Yan, G., Wang, P., & Wang, X. (2015) · BioMed Research International · doi:10.1155/2015/354671 · Cited by 286
Metadata
- Authors
- Patterson, A. D., Maurhofer, O., Beyoğlu, D., Lanz, C., Krausz, K. W., Pabst, T., Gonzalez, F. J., Dufour, J.-F., & Idle, J. R.
- Venue
- Cancer Research
- Published
- 2011-10-30
- Volume
- 71
- Issue
- 21
- Pages
- 6590-6600
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2151893606
- Cited by
- 268
- References
- 38
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid Profiling. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-0885
- The paper
- Patterson, A. D., Maurhofer, O., Beyoğlu, D., Lanz, C., Krausz, K. W., Pabst, T., Gonzalez, F. J., Dufour, J.-F., & Idle, J. R. (2011). Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid Profiling. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-0885
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.